RVTYHealthcare · Diagnostics & ResearchThe 18 Wall Street analysts covering Revvity, Inc. hold a median 12-month price target of $160 — +5.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Revvity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Growth (56): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RVTY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.2% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $130 → $175 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | $115 → $160 |
| 6 Oct 2026 | William Blair | Initiates | Outperform | — |
| 9 Sept 2026 | UBS | Assumes | Neutral | $120 → $140 |
| 4 Sept 2026 | Keybanc | Maintains | Overweight | — |
| 4 Sept 2026 | Keybanc | Maintains | Overweight | $125 → $165 |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | — |
| 1 Sept 2026 | RBC Capital | Initiates | Sector Perform | $135 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $125 → $126 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $110 → $125 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $115 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | JP Morgan | Maintains | Neutral | — |
| 6 May 2026 | Stifel | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Buy | — |
| 4 May 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVTY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Revvity, Inc. returned +67.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 10% of US stocks
Cheaper than 21% of US stocks
Cheaper than 37% of US stocks
Cheaper than 13% of US stocks
Higher than 30% of US stocks
Higher than 32% of US stocks
Higher than 70% of US stocks
Higher than 75% of US stocks
Higher than 66% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 63% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revvity, Inc. has a market value of $17.3B and an enterprise value of $19.6B.
Revenue in the twelve months to 30 June 2026: $2.9B. The latest quarter grew 1.3% year on year.
Net income over the same four quarters: $237.6M, a 8.2% net margin.
Diluted earnings per share, trailing twelve months: $2.09.
Free cash flow in the twelve months to 30 June 2026: $558.1M, after $69.5M of capital spending.
Revvity, Inc. spent $475.8M on share buybacks and $31.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.2×; forward P/E: 26.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.18%, paying out 13% of earnings.
Revvity, Inc. employs 11,000 people — $265K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Revvity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Danaher announced plans to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The announcement was described as a turning point for life science automation, though Danaher’s stock barely moved that day.
Why it matters — The development highlights activity in AI-enabled laboratory automation, an area relevant to watchers of life science tools companies such as Revvity.
Revvity announced that CEO Prahlad Singh will present at the 2026 Jefferies Global Healthcare Conference on November 17 and the 9th Annual Evercore Healthcare Conference on December 2. The company said attendees will receive updates on Revvity and its strategic priorities during fireside chats.
Why it matters — The presentations provide RVTY watchers with scheduled opportunities to hear company updates and strategic priorities from its CEO.
Revvity announced it will host its 2026 Investor Day on Friday, November 13, at 9:00 a.m. ET. Senior management will discuss key business initiatives, operational achievements and the company’s financial outlook.
Why it matters — Investors can hear management updates on Revvity’s business and financial outlook during the webcast.
Zacks Investment Research upgraded Revvity (RVTY) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The upgrade signals a more favorable near-term outlook for the stock.
Why it matters — An analyst upgrade to Buy reflects improved expectations for Revvity's earnings, which could influence investor sentiment and trading activity in the stock.
Revvity, Inc. announced it will release its third quarter 2026 financial results before market open on Tuesday, November 3, 2026, and will host a conference call the same day at 7:30 a.m. ET. CEO Prahlad Singh and CFO Max Krakowiak will lead the call, which will be available via a live audio webcast on the Investors section of the company's website.
Why it matters — This announcement gives RVTY watchers the date and time for when they can hear management discuss the company's third quarter performance directly.
The 18 Wall Street analysts covering Revvity, Inc. have a median 12-month price target of $160, with estimates ranging from $110 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Revvity, Inc., 6 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Revvity, Inc. 95 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Revvity, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +5.2% from the last close, and Ticker Nerd's factor model ranks Revvity, Inc. 95 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revvity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVTY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $175 over the next 12 months.
Revvity, Inc. returned +67.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing.
The most recent item we track (ETF Trends, 14 Oct 2026): "How to Invest in AI Drug Discovery". Danaher announced plans to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The announcement was described as a turning point for life science automation, though Danaher’s stock barely moved that day.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
CEO Dr. Prahlad R. Singh Ph.D. · 11,000 employees · United States · https://www.revvity.com
